Expectations are rising for PO use for injectable insulin. Medicox recently signed an exclusive distribution contract with Israeli pharmaceutical company Oramed Pharmaceuticals following the introduction of oral insulin technology. As a result, Medicox will be able to distribute Oramed's oral insulin candidate "ORMD-0801" for 10 years in Korea after approval by the Ministry of Food and Drug Safety. Oramed is said to be innovating the diabetes treatment market through the development of ORMD-0801, which is undergoing phase 3. Topline results of Phase 3 will be released in January 2023, and ORMD-0801 is expected to be the world's first commercial oral insulin capsule for diabetes treatment in the future.